A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors

Summary

The purpose of this study is to evaluate the safety, tolerance, Dose-Limiting Toxicity (DLT), Maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ES102 (OX40 Agonist) administered as a single agent in patients with advanced solid tumors.

Timeline

Start

2021-04-01

Primary completion

2024-03-01

Completion

2024-03-01

Drugs

Indications